Vivani Medical (VANI) Stock Price, News & Analysis

Company Overview

Vivani Medical, Inc. (NASDAQ: VANI) is a biopharmaceutical company developing miniature, long-term implantable drug-delivery systems for chronic diseases. Its proprietary NanoPortal technology is designed to deliver medication continuously over extended periods, potentially reducing the need for frequent injections or daily dosing.

The company’s pipeline has focused primarily on treatments based on glucagon-like peptide-1 (GLP-1) therapies. Its lead candidates have included NPM-115, an implantable formulation of exenatide being developed for chronic weight management, and NPM-119, an exenatide-based implant intended to treat type 2 diabetes. Vivani has also evaluated additional applications of its implant technology for other metabolic and chronic conditions.

Vivani is headquartered in Fremont, California, and its development activities have primarily been directed toward the U.S. pharmaceutical and biotechnology market. The company originated from Nano Precision Medical, Inc. and became a publicly traded company through a business combination involving Second Sight Medical Products. Vivani is led by President and Chief Executive Officer Adam Mendelsohn, Ph.D.

Key Stats

• Today's Range: $1.17 to $1.23
• 50-Day Range: $1.19 to $1.49
• 52-Week Range: $0.92 to $1.92
• Volume: 904,413 shs
• Average Volume: 208,693 shs
• Market Capitalization: $107.34 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $3.75
• Consensus Rating: Hold

Vivani Medical Stock Analysis - MarketRank™

Vivani Medical scored higher than 68% of companies evaluated by MarketBeat, and ranked 227th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.5 / 5
• Analyst Rating: Hold

Consensus Rating

Vivani Medical has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on no strong buy ratings, 2 buy ratings, 1 hold rating, and 1 sell rating.

Upside Potential

Vivani Medical has a consensus price target of $3.75, representing about 215.1% upside from its current price of $1.19.

Amount of Analyst Coverage

Vivani Medical has only been the subject of 2 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Vivani Medical are expected to grow in the coming year, from ($0.30) to ($0.27) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Vivani Medical is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Vivani Medical is -3.40, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Vivani Medical has a P/B Ratio of 5.95. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

1.18% of the float of Vivani Medical has been sold short.

Short Interest Ratio / Days to Cover

Vivani Medical has a short interest ratio ("days to cover") of 2.17, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Vivani Medical has recently decreased by 6.58%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Vivani Medical does not currently pay a dividend.

Dividend Growth

Vivani Medical does not have a long track record of dividend growth.

News and Social Media

• Score: 3.2 / 5
• News Sentiment: N/A

News Sentiment

Vivani Medical has a news sentiment score of 1.05. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Vivani Medical this week, compared to 2 articles on an average week.

MarketBeat Follows

4 people have added Vivani Medical to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.8 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Vivani Medical insiders have not sold or bought any company stock.

Percentage Held by Insiders

53.30% of the stock of Vivani Medical is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

6.78% of the stock of Vivani Medical is held by institutions.

Company Calendar

• Last Earnings: 8/13/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 11/12/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Pharmaceuticals
• Sub-Industry: Pharmaceuticals
• Current Symbol: NASDAQ:VANI
• CIK: 1266806
• Web: www.vivani.com
• Phone: (415) 506-8462
• Fax: 818-833-5067
• Employees: 36
• Year Founded: N/A

Price Target and Rating

• Average Price Target for Vivani Medical: $3.75
• High Price Target: $4.00
• Low Price Target: $3.50
• Potential Upside/Downside: +215.1%
• Consensus Rating: Hold
• Rating Score (0-4): 2.25
• Research Coverage: 4 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.35)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$26.61 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -191.05%
• Return on Assets: -70.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 3.25
• Quick Ratio: 3.25

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.20 per share
• Price / Book: 5.95

Miscellaneous

• Outstanding Shares: 90,200,000
• Free Float: 42,125,000
• Market Cap: $107.34 million
• Optionable: Optionable
• Beta: 2.36